We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Kui Lin - Principal Scientist, Translational Oncology

Kui Lin

Principal Scientist, Translational Oncology

"The most rewarding part of working here is to be able to not only do cutting edge science, but also see our research being tested in the clinic, and eventually benefit human patients."
20
Years at Genentech
1
Publications

I joined Genentech after my postdoc training at UCSF. Genentech was my first choice as I knew it was the best blend of academic and industry cultures.

The most rewarding part of working here is to be able to not only do cutting edge science, but also see our research being tested in the clinic, and eventually benefit human patients.

Featured Publication

An ATP-site on-off switch that restricts phosphatase accessibility of Akt.

Science Signaling 5 (223): ra37.

Lin, K., Lin J., Wu, W-I., Ballard, J., Lee, B., Gloor, S., Vigers, G., Morales, T., Friedman, L., Skelton, N. and Brandhuber, B.